Akreos MICS lens gets the thumbs up

Article

Cataract surgery with the Akreos MI60 microincision lens (Bausch & Lomb) is a safe and effective procedure.

Cataract surgery with the Akreos MI60 microincision lens (Bausch & Lomb) is a safe and effective procedure, according to Jorge Alio and co-workers from VISSUM Instituto Oftalmologica de Alicante, Spain and study groups in France, Germany, Italy and Sweden.

The study enrolled 98 eyes to be implanted with the Akreos lens using bimanual phaco with the Millenium system (Bausch & Lomb), a wound-assisted MI60 lens implantation and a 1.8 mm cartridge. Mean age of subjects was 70 years and the mean preoperative spherical equivalent was -0.53±2.93 D.

The corneal incision changed from a pre-implant value of 1.68±0.24 mm to a post-implant value of 1.82±0.16 mm, implying a wound stretch with implantation of 0.14±0.22 mm. Postoperative spherical equivalent was -0.05±0.90 D, while best corrected visual acuity (BCVA) improved from 0.42±0.25 to 0.04±0.18.

The research group believe that cataract surgery using the Akreos MI60 microincision lens produces excellent visual and refractive outcomes.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.